Application of phosphatidylcholine as marker in preparation of kit for detecting diabetic kidney disease
By using phosphatidylcholine as a marker in the diabetic nephropathy test kit and combining it with detection technology, the limitations of existing screening indicators in the early diagnosis of DKD are overcome, accurate differentiation between patients with type 2 diabetes and diabetic nephropathy is achieved, and a basis for early diagnosis is provided.
Patent Information
- Application Number
- CN202510741922.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-05
- Publication Date
- 2025-09-12
AI Technical Summary
Existing screening indicators such as eGFR and UACR have limitations in clinical judgment of diabetic kidney disease, making it difficult to identify DKD patients early. New biomarkers are needed for early diagnosis.
Phosphatidylcholine was used as a marker to prepare a kit for detecting diabetic nephropathy. The concentration difference of phosphatidylcholine in urine was detected by ultra-performance liquid chromatography-tandem mass spectrometry, and diagnosis was made by combining binary logistic regression analysis.
It achieved accurate differentiation between patients with type 2 diabetes and diabetic nephropathy, with an area under the ROC curve (AUC) of 0.788, a sensitivity of 64.5%, and a specificity of 88.2%, providing a basis for early diagnosis of DKD.